USPTO serial 99285352
ECOTERA
Status 688Notice of Allowance
- Filing date
- Jul 15, 2025
- Status date
- May 12, 2026
- Registration date
- —
- Examiner
- HARMON KENNEDY, HEATHER N
Need help with ECOTERA?
CopyMark Law Group can help you respond to USPTO correspondence, keep a registration alive, or watch new filings against your mark.
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Deadline: November 12th, 2026
Owner
Melinda B Chu
Blue Ash, OH, US
Melinda B Chu
Blue Ash, OH, US
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in urology; Cardiovascular pharmaceutical preparations; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for Inflammation, Cardiovascular diseases, Gastrointestinal disorders, Neurodegenerative diseases including dementia and cognitive disorders, Endocrine disorders, Immune system disorders, Metabolic syndrome, Reproductive health including urological disorders, Environmental toxin-related diseases, Microplastic-induced diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Therapeutic pharmaceutical for the treatment of Inflammation, Cardiovascular disease, Gastrointestinal disorders, Neurodegenerative diseases including dementia and cognitive disorders, Endocrine disorders, Immune system disorders Metabolic syndrome Reproductive health including urological disorders Environmental toxin-related diseases Microplastic-induced diseases; Plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes | ACTIVE | — |
Prosecution history
| Date | Code | Event |
|---|---|---|
| May 12, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Apr 1, 2026 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Feb 6, 2026 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Jan 20, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jan 20, 2026 | PUBO | PUBLISHED FOR OPPOSITION |
| Jan 14, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 17, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Dec 3, 2025 | DOCK | ASSIGNED TO EXAMINER |
| Jul 15, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED |
| Jul 15, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jul 15, 2025 | NWAP | NEW APPLICATION ENTERED |